A phase 2 liver trial where the add-on drug didn't help — and the base drug quietly did
Read the Sunday Brief →

Study wrapper · #955

A single-centre, prospective, qualitative analysis of knowledge, attitudes and behaviour of sunbed use among patients attending a pigmented lesion clinic.

Lai FY, Quigley C, Murray G, et al. Skin health and disease. 2025.

Editor's note

This qualitative survey of sunbed users documents concurrent use of unregulated Melanotan I and II among tanning-focused patients and flags associated public-health risks such as blood-borne infection from injectable use. The peptides are examined as part of tanning behavior rather than for physiological effect. It offers useful real-world context on unregulated melanotan use.

Plain-language abstract

A survey of sunbed users at a dermatology clinic found that many also used unregulated tan-enhancing agents such as Melanotan I and II, raising concerns including blood-borne infection risk.